Compare PJT & KNSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PJT | KNSA |
|---|---|---|
| Founded | 2014 | 2015 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.9B | 3.5B |
| IPO Year | 2015 | 2018 |
| Metric | PJT | KNSA |
|---|---|---|
| Price | $152.38 | $52.44 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 7 |
| Target Price | ★ $174.25 | $58.43 |
| AVG Volume (30 Days) | 317.4K | ★ 742.4K |
| Earning Date | 04-28-2026 | 04-28-2026 |
| Dividend Yield | ★ 0.65% | N/A |
| EPS Growth | N/A | ★ 225.00 |
| EPS | N/A | ★ 0.27 |
| Revenue | ★ $1,713,671,000.00 | $677,564,000.00 |
| Revenue This Year | $11.12 | $37.48 |
| Revenue Next Year | $9.98 | $17.87 |
| P/E Ratio | ★ $23.03 | $71.19 |
| Revenue Growth | 14.77 | ★ 60.09 |
| 52 Week Low | $127.73 | $25.71 |
| 52 Week High | $195.62 | $54.23 |
| Indicator | PJT | KNSA |
|---|---|---|
| Relative Strength Index (RSI) | 51.14 | 66.79 |
| Support Level | $127.73 | $40.67 |
| Resistance Level | $186.13 | N/A |
| Average True Range (ATR) | 5.53 | 2.20 |
| MACD | -0.58 | 0.68 |
| Stochastic Oscillator | 26.38 | 85.60 |
PJT Partners Inc is an advisory-focused investment bank that offers a portfolio of advisory services designed to help its clients achieve their strategic objectives. The company delivers a range of strategic advisory, capital markets advisory, restructuring and special situations, and shareholder advisory services to corporations, financial sponsors, institutional investors, and governments around the world. It also provides private fund advisory and fundraising services for alternative investment strategies, including private equity, real estate, hedge funds, and private credit. The company generates its revenue from advisory fees, placement services, and others. Geographically, it generates maximum revenue from the United States, followed by the United Kingdom and other markets.
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating cardiovascular diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and Vixarelimab. Geographically, the company earns maximum revenue from United States.